当前位置: X-MOL 学术Neurol. Sci. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting.
Neurological Sciences ( IF 3.3 ) Pub Date : 2020-05-10 , DOI: 10.1007/s10072-020-04367-9
R Lanzillo 1 , M Sparaco 2 , L Lavorgna 2 , L Carmisciano 3 , E Signoriello 2 , A Signori 3 , T Costabile 1 , G T Maniscalco 4 , F Saccà 1 , S Cepparulo 2 , C V Russo 1 , A Bisecco 2 , N Frattaruolo 1 , A Strianese 1 , G Lus 2 , V Brescia Morra 1 , S Bonavita 2
Affiliation  

BACKGROUND Patient-reported outcomes (PROs) may help patients and clinicians in selecting disease-modifying therapies (DMTs) for multiple sclerosis (MS). OBJECTIVE To evaluate PRO differences among first-line DMTs for relapsing-remitting (RR) people with MS (pwMS). METHODS Multicenter study. RR pwMS on first-line DMTs completed Fatigue Severity Scale (FSS), PROs Indices for MS (PRIMUS), 36-item Short-Form Health Survey (SF-36), treatment satisfaction questionnaire for medication (TSQM), Beck Depression Inventory-II (BDI-II), and Symbol Digit Modalities Test (SDMT). Differences among PROs across DMTs were tested by ANOVA. Multivariable linear regressions were used to investigate associations between PROs and the treatment group. RESULTS Two-hundred eighty pwMS were enrolled: 56% were on interferons (INF), 22% on dimethylfumarate (DMF), 13% on glatiramer acetate, and 9% on teriflunomide (Teri). Compared with INF, pwMS on Teri were the oldest, with higher disability, worst depression at BDI, worst cognitive performances at SDMT (p = 0.001), fatigue at FSS (p = 0.001), and activity limitation and quality of life respectively at PRIMUS (p = 0.005) and SF-36 Mental Composite Score (p < 0.001); pwMS on DMF reported highest side effects and, together with pwMS on Teri, better treatment satisfaction at TSQM. CONCLUSIONS Compared with INF-treated patients, pwMS on DMF and Teri reported the best treatment satisfaction, although DMF-treated pwMS reported higher side effects and those on Teri the worst QoL and fatigue; however, the older age, higher disability and depression, and worse cognitive performance of pwMS on Teri suggest to be careful in evaluating these results.

中文翻译:

在现实世界中,对一线疗法的多发性硬化症患者进行患者报告的预后测量的快照。

背景技术患者报告的结局(PRO)可以帮助患者和临床医生选择用于多发性硬化症(MS)的疾病改变疗法(DMT)。目的评估一线DMT在MS复发性缓解(RR)患者中的PRO差异。方法多中心研究。一线DMT的RR pwMS已完成疲劳严重程度量表(FSS),MS的PRO指标(PRIMUS),简短项目健康调查(SF-36),药物治疗满意度问卷(TSQM),贝克抑郁量表- II(BDI-II)和符号数字模态测试(SDMT)。通过ANOVA测试了跨DMT的PRO之间的差异。多变量线性回归用于研究PRO与治疗组之间的关联。结果招募了280名pwMS:干扰素(INF)占56%,富马酸二甲酯(DMF)占22%,醋酸格拉替雷13%,特氟米特(Teri)9%。与INF相比,Teri的pwMS年龄最大,残疾更高,BDI抑郁最严重,SDMT认知能力最差(p = 0.001),FSS疲劳(p = 0.001)以及PRIMUS的活动受限和生活质量(p = 0.005)和SF-36心理综合评分(p <0.001);pwMS在DMF上的副作用最大,并且与peri在Teri上的副作用一起,在TSQM上具有更好的治疗满意度。结论与INF治疗的患者相比,DMF和Teri的pwMS的治疗满意度最高,尽管DMF治疗的pwMS的副作用更高,而Teri的QoL和疲劳最差。但是,pwMS在Teri上年龄较大,残疾和抑郁较高,并且认知表现较差,因此建议谨慎评估这些结果。
更新日期:2020-05-10
down
wechat
bug